Souhaitez-vous accéder aux communiqués récents ?

Monte Rosa Therapeutics to Present Interim MRT-8102 Phase 1 Study Results

ISELIN, N.J., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Provident Financial Services, Inc. (NYSE: PFS) announced that it expects to release financial results for the quarter ended December 31, 2025 on...

CHENNAI, India, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Sify Technologies Limited (NASDAQ: SIFY), India’s leading Digital ICT solutions provider with global service capabilities spanning Data Center,...

Ongoing Enrollment Continues in VALUE Phase III Trial of EscharEx® in Venous Leg Ulcers Commissioning Completed for Expanded NexoBrid® Facility; Full Operational Capacity Expected by Year-End 2025 ...

BOISE, Idaho, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Micron Technology, Inc. (Nasdaq: MU) announced today that it will hold its fiscal first quarter earnings conference call on Wednesday, Dec. 17, 2025,...

Agios today announced topline results from the 52-week double-blind period of the global RISE UP Phase 3 trial

OTTAWA, Ontario, 14 nov. 2025 (GLOBE NEWSWIRE) -- CalianMD Group Ltd. (TSX : CGY), une société de solutions essentielles axée sur la défense, l'espace, les soins de santé et d'autres secteurs...

Calian® Group Ltd., will hold a conference call at 8:30 a.m. Eastern Time on Wednesday, November 26, 2025, to discuss Q4 FY 2025 results.

KULR Technology Group, Inc. (NYSE American: KULR) November 18th at 4:30 p.m. Eastern time (1:30 p.m. Pacific time)

Third quarter 2025 net revenues were $17.6 million Emrosi™ total prescriptions increased 146% over the second quarter of 2025 Emrosi net revenues were $4.9 million Company to hold conference call...